Systemic Mastocytosis: Clinical Update and Future Directions

Area of Science:

• Hematology
• Oncology
• Rare Diseases

Background:

• Systemic mastocytosis (SM) is characterized by abnormal mast cell (MC) accumulation in extracutaneous tissues.
• Symptoms arise from MC activation or organ infiltration, with disease subtypes exhibiting variable prognoses.
• Indolent SM has a normal life expectancy, whereas aggressive subtypes like MC leukemia (MCL) have a median survival of months.

Purpose of the Study:

• To familiarize clinicians with systemic mastocytosis, an orphan disease.
• To review current and future treatment strategies for diverse SM subtypes.
• To address the clinical heterogeneity and diagnostic challenges of SM.

Main Methods:

• Literature review of current and emerging treatments for SM.
• Analysis of therapeutic approaches based on disease indolence and aggressiveness.
• Discussion of stem cell transplantation as a potentially curative option.

Main Results:

• Treatment for indolent SM focuses on symptom control.
• Advanced SM and MCL may be treated with KIT inhibitors, cladribine, or thalidomide.
• Hematopoietic stem cell transplantation is the sole potentially curative option for aggressive SM/MCL.

Conclusions:

• Clinicians require enhanced understanding to manage SM due to its rarity and heterogeneity.
• Current treatments target MC activation or proliferation, with ongoing investigation into novel agents.
• Effective management necessitates tailored approaches, from palliative care to potentially curative transplantation.